Sigilon Therapeutics Analysis

Sigilon Stock Analysis Notes

About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.25. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sigilon Therapeutics recorded a loss per share of 14.83. The entity had not issued any dividends in recent years. The firm had 1:13 split on the 23rd of May 2023. Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people. To find out more about Sigilon Therapeutics contact MBA MD at 617 336 7540 or learn more at https://www.sigilon.com.

Sigilon Therapeutics Investment Alerts

Sigilon Therapeutics Upcoming and Recent Events

Sigilon Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 56.22 M.

Sigilon Profitablity

The company has Profit Margin (PM) of (1.71) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.75) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.75.

Sigilon Therapeutics Insider Trading Activities

Sigilon Therapeutics Outstanding Bonds

Sigilon Therapeutics Predictive Daily Indicators

Stock analysis is the technique used by a trader or investor to examine and evaluate how Sigilon Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sigilon shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Sigilon Therapeutics. By using and applying Sigilon Stock analysis, traders can create a robust methodology for identifying Sigilon entry and exit points for their positions.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.